251 related articles for article (PubMed ID: 33828551)
21. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets.
Holmøy T
Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322
[TBL] [Abstract][Full Text] [Related]
22. CD30 antigen and multiple sclerosis: CD30, an important costimulatory molecule and marker of a regulatory subpopulation of dendritic cells, is involved in the maintenance of the physiological balance between TH1/TH2 immune responses and tolerance. The role of IFNbeta-1a in the treatment of multiple sclerosis.
Pellegrini P; Totaro R; Contasta I; Berghella AM; Carolei A; Adorno D
Neuroimmunomodulation; 2005; 12(4):220-34. PubMed ID: 15990453
[TBL] [Abstract][Full Text] [Related]
23. Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.
Pires LR; Marques F; Sousa JC; Cerqueira J; Pinto IM
Hum Vaccin Immunother; 2016 Jul; 12(7):1886-90. PubMed ID: 26890336
[TBL] [Abstract][Full Text] [Related]
24. The small heat shock protein alpha B-crystallin as key autoantigen in multiple sclerosis.
Van Noort JM; van Sechel AC; van Stipdonk MJ; Bajramovic JJ
Prog Brain Res; 1998; 117():435-52. PubMed ID: 9932424
[No Abstract] [Full Text] [Related]
25. Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
Karussis D; Slavin S
J Neurol Sci; 2004 Aug; 223(1):59-64. PubMed ID: 15261562
[TBL] [Abstract][Full Text] [Related]
26. Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future.
Derdelinckx J; Cras P; Berneman ZN; Cools N
Front Immunol; 2021; 12():624685. PubMed ID: 33679769
[TBL] [Abstract][Full Text] [Related]
27. Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials.
Flórez-Grau G; Zubizarreta I; Cabezón R; Villoslada P; Benitez-Ribas D
Front Immunol; 2018; 9():1169. PubMed ID: 29904379
[TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis. Presenting an odd autoantigen.
Steinman L
Nature; 1995 Jun; 375(6534):739-40. PubMed ID: 7541112
[No Abstract] [Full Text] [Related]
29. Immune tolerance and control of CNS autoimmunity: from animal models to MS patients.
Cassan C; Liblau RS
J Neurochem; 2007 Feb; 100(4):883-92. PubMed ID: 17181557
[TBL] [Abstract][Full Text] [Related]
30. Antigen dynamics govern the induction of CD4(+) T cell tolerance during autoimmunity.
Challa DK; Mi W; Lo ST; Ober RJ; Ward ES
J Autoimmun; 2016 Aug; 72():84-94. PubMed ID: 27236506
[TBL] [Abstract][Full Text] [Related]
31. DNA-based vaccines for multiple sclerosis: current status and future directions.
Fissolo N; Montalban X; Comabella M
Clin Immunol; 2012 Jan; 142(1):76-83. PubMed ID: 21163708
[TBL] [Abstract][Full Text] [Related]
32. Analysis of antigen specific T cells in diabetes - Lessons from pre-clinical studies and early clinical trials.
Krishnamurthy B; Selck C; Chee J; Jhala G; Kay TW
J Autoimmun; 2016 Jul; 71():35-43. PubMed ID: 27083395
[TBL] [Abstract][Full Text] [Related]
33. Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins.
Brändle SM; Obermeier B; Senel M; Bruder J; Mentele R; Khademi M; Olsson T; Tumani H; Kristoferitsch W; Lottspeich F; Wekerle H; Hohlfeld R; Dornmair K
Proc Natl Acad Sci U S A; 2016 Jul; 113(28):7864-9. PubMed ID: 27325759
[TBL] [Abstract][Full Text] [Related]
34. [Role of T-regulatory cells in multiple sclerosis].
Rojas JI; González SJ; Patrucco L; Cristiano E
Medicina (B Aires); 2010; 70(1):79-86. PubMed ID: 20228030
[TBL] [Abstract][Full Text] [Related]
35. Yin-Yang regulation of autoimmunity by DCs.
't Hart BA; van Kooyk Y
Trends Immunol; 2004 Jul; 25(7):353-9. PubMed ID: 15207502
[No Abstract] [Full Text] [Related]
36. Immunopathological recognition of autoantigens in multiple sclerosis.
Bernard CC; de Rosbo NK
Acta Neurol (Napoli); 1991 Apr; 13(2):171-8. PubMed ID: 1891982
[TBL] [Abstract][Full Text] [Related]
37. Reduced experimental autoimmune encephalomyelitis after intranasal and oral administration of recombinant lactobacilli expressing myelin antigens.
Maassen CB; Laman JD; van Holten-Neelen C; Hoogteijling L; Groenewegen L; Visser L; Schellekens MM; Boersma WJ; Claassen E
Vaccine; 2003 Dec; 21(32):4685-93. PubMed ID: 14585676
[TBL] [Abstract][Full Text] [Related]
38. Antigen-presenting cells and tolerance induction.
von Bubnoff D; de la Salle H; Wessendorf J; Koch S; Hanau D; Bieber T
Allergy; 2002 Jan; 57(1):2-8. PubMed ID: 11991283
[TBL] [Abstract][Full Text] [Related]
39. Antigen presentation in MHC class II transgenic mice: stimulation versus tolerization.
Lo D; Burkly LC; Flavell RA; Palmiter RD; Brinster RL
Immunol Rev; 1990 Oct; 117():121-34. PubMed ID: 2258189
[No Abstract] [Full Text] [Related]
40. Immunological update on multiple sclerosis.
Hohlfeld R; Wekerle H
Curr Opin Neurol; 2001 Jun; 14(3):299-304. PubMed ID: 11371751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
